Updates on the Treatment of Erythrodermic Psoriasis
Yang Lo,Tsen-Fang Tsai
DOI: https://doi.org/10.2147/PTT.S288345
2021-06-10
Psoriasis: Targets and Therapy
Abstract:Yang Lo, 1 Tsen-Fang Tsai 2 1 Department of Dermatology, Cathay General Hospital, Taipei, Taiwan; 2 Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan Correspondence: Tsen-Fang Tsai Tel +886-2-2312-3456 #65734 Email Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP. Keywords: erythrodermic psoriasis, treatment Erythrodermic psoriasis (EP), a rare variant of psoriasis vulgaris, accounts for 1–2% patients with psoriasis. 1 , 2 A higher prevalence of EP in Asians was found in China and Taiwan study. 3 , 4 EP is clinically defined as prominent erythema and scaling affecting at least 75–90% of the body surface area (BSA). 1 , 5 Due to the extensive cutaneous involvement, EP patients can present with systemic symptoms, such as pruritus, fever, chills, dehydration, arthralgia, asthenia and lymphadenopathy. 1 , 5 Several triggers for causing EP can be identified, including infection, administration of systemic corticosteroids, withdrawal of medication, severe emotional stress and preceding illness. 2 , 6 Many biomarkers are possibly related to the pathogenesis of EP, including higher IL-4 and IL-10 levels, 7 elevation of serum IgE, 8 increased Th2 response, 7 , 9 and the presence of circulating adhesion molecules. 10 There may be overlap between the EP and atopic dermatitis immune phenotypes. 11 Recently, a study from China revealed the possible role of the cytokine tumor necrosis factor-related weak inducer of apoptosis (TWEAK) in the pathogenesis of EP and psoriasis vulgaris (PV). 12 Furthermore, according to a recent study from China, a higher prevalence of thyroid dysfunction was found in EP patients. 13 Several human leukocyte antigens (HLA), such as HLA-Cw6 and HLA-DR7 have been linked with psoriasis vulgaris, 14 , 15 and the same genetic constitution was also related to guttate psoriasis. 16 In Chinese patients with erythrodermic psoriasis, HLA-C*01:02 was reported to be the most frequent HLA-C allele (34.4%) compared to plaque psoriasis (21.9%) and healthy controls (21.2%). 6 Recently, one case reported mutations of the CARD14 gene with EP related to requiring higher doses of ustekinumab. 17 Due to the lack of head-to-head studies and the rarity of EP, no high-level evidence-based treatment guidelines for EP have been established. 1 This review article aims to provide up-to-date information for the treatment of EP ( Tables 1 – 5 ). Table 1 Studies of Conventional Oral Immunosuppressive Agents in EP Patients Table 2 Studies of Tumor Necrosis Factor Antagonist in EP Patients Table 3 Studies of IL‐12/23, IL-23 Antagonist in EP Patients Table 4 Studies of IL‐17 Antagonist in EP Patients Table 5 Other Treatment in EP Patients The electronic databases of PubMed, Embase and Google Scholar were searched for relevant studies from 1985 to March 1, 2021, using the index words, "erythrodermic psoriasis" and the co-indexing terms "treatment", "management", "biologic", " methotrexate", "cyclosporine", "acitretin", " etanercept", "infliximab", "adalimumab", "ustekinumab", "secukinumab", "ixekizumab", "brodalumab", "guselkumab", " tildrakizumab", "risankizumab" and "apremilast". Methotrexate (MTX) is one of the most commonly used immunosuppressive drugs for EP. 18–24 The treatment dosing is variable for the initial dose; the administration of 7.5 to 15mg per week for maintenance -Abstract Truncated-